Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96
- PMID: 9430473
Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96
Abstract
Based on the biodistribution and kinetics of biotinylated 188Re-chimeric BR96 (chiBR96), the enhancement of the tumor-to-normal tissue (T/N) radioactivity ratio using extracorporeal immunoadsorption (ECIA) was evaluated and compared with that of avidin "chase" in colon carcinoma-isografted Brown Norwegian rats.
Methods: Extracorporeal immunoadsorption (ECIA) was performed 6 or 12 hr after intravenous administration of biotinylated 188Re-chiBR96. Radioactivity redistribution was investigated just after ECIA [8 or 14 hr postinjection of the antibody] and 40 or 34 hr after ECIA performance (48 hr postinjection). Avidin was administered intraperitoneally at 6 hr postinjection. Tumor radioactivity uptake and T/N activity ratios of biotinylated 188Re-chiBR96 were compared using ECIA and avidin chase and were also compared with controls.
Results: Both ECIA and avidin chase can rapidly increase the radioactivity tumor-to-blood ratio without significantly interfering with the tumor uptake. ECIA at 8 hr postinjection increased the T/N ratios in blood-rich tissues, such as liver and bone marrow, from 6 and 8 to 10 and 18, respectively. Corresponding T/N ratios at 14 hr increased from 9 and 10 to 24 and 36. In contrast, when avidin chase was used, there were no T/N improvements, except in blood. Moreover, avidin chase caused a significant accumulation of radioactivity in the liver.
Conclusion: The ECIA approach, with direct removal of unbound circulating biotinylated 188Re-chiBR96, thus can rapidly improve and maintain T/N ratios without overloading the liver with radioactivity, in contrast to avidin chase.
Similar articles
-
Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.Clin Cancer Res. 1999 Oct;5(10 Suppl):3059s-3064s. Clin Cancer Res. 1999. PMID: 10541344
-
Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.Cancer. 1997 Dec 15;80(12 Suppl):2411-8. Cancer. 1997. PMID: 9406691
-
Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.J Nucl Med. 1997 Jun;38(6):895-901. J Nucl Med. 1997. PMID: 9189138
-
188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology.Nucl Med Biol. 1998 Jul;25(5):441-7. doi: 10.1016/s0969-8051(98)00008-0. Nucl Med Biol. 1998. PMID: 9720661 Review.
-
Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors--a review of radiolabeling characteristics, quality control and in vitro stability studies.Appl Radiat Isot. 2001 Mar;54(3):399-406. doi: 10.1016/s0969-8043(00)00277-3. Appl Radiat Isot. 2001. PMID: 11214873 Review.
Cited by
-
Labeling biomolecules with radiorhenium: a review of the bifunctional chelators.Anticancer Agents Med Chem. 2007 May;7(3):367-77. doi: 10.2174/187152007780618144. Anticancer Agents Med Chem. 2007. PMID: 17504162 Free PMC article. Review.
-
Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice.Jpn J Cancer Res. 2000 Jun;91(6):622-8. doi: 10.1111/j.1349-7006.2000.tb00991.x. Jpn J Cancer Res. 2000. PMID: 10874215 Free PMC article.
-
Emerging trends for radioimmunotherapy in solid tumors.Cancer Biother Radiopharm. 2013 Nov;28(9):639-50. doi: 10.1089/cbr.2013.1523. Epub 2013 Jul 11. Cancer Biother Radiopharm. 2013. PMID: 23844555 Free PMC article. Review.
-
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.Cancer Biother Radiopharm. 2010 Feb;25(1):1-12. doi: 10.1089/cbr.2009.0690. Cancer Biother Radiopharm. 2010. PMID: 20187791 Free PMC article.
-
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.Adv Drug Deliv Rev. 2008 Sep;60(12):1347-70. doi: 10.1016/j.addr.2008.04.006. Epub 2008 Apr 23. Adv Drug Deliv Rev. 2008. PMID: 18538888 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources